Speakers: Daniel Murphy, DC, DABCO & Steven Shanks, the President of Erchonia Corporation
Sign up for this Webinar to Learn:
➔ Integrate concepts in laser photon therapy: wavelength, frequency, speed of light, fluence, penetration, secondary and primary physiological influences.
➔ Contrast the differences between thermal and non-thermal laser therapy.
➔ Develop the relationship between mitochondria, free radicals, ATP, cytochrome c oxidase enzyme, and laser photon therapy.
➔ Discuss the physiology of applying laser therapy to both the anatomical part of injury/complaint and to the nerve roots that innervate that anatomical part.
➔ Explain the biphasic nature of laser photon therapy as related to evolutionary biology and current clinical applications.
About the Speakers:
Daniel Murphy, DC, DABCO is a well-recognized, award-winning chiropractor and a popular instructor who teaches internationally while maintaining a part-time clinical practice. He has taught over 1,610 twelve-hour postgraduate continuing education classes. He also serves as a part-time undergraduate faculty professor at Life Chiropractic College West, where he is currently teaching classes to seniors in the management of spinal disorders. He has taught post-graduate classes for a long list of chiropractic colleges and individual programs. He is a contributing author to several books and a quarterly columnist in the American Journal of Clinical Chiropractic. From 2003 – 2009, Daniel Murphy, DC, DABCO served as the Vice President of the International Chiropractic Association. In 2014, he was awarded the Lifetime Achievement Award from the International Association of Functional Neurology and Rehabilitation (IAFNR).
Steven Shanks, the President of Erchonia Corporation; stands at the forefront of medical innovation and the growth of low level laser technology. He has spent the last 20 years advocating and promoting bio-modulation as an alternative modality to invasive procedures and primary treatment. A calculated risk-taker, with a profound understanding of clinical research, he has devoted his knowledge to researching applications that advance safe, effective, and non-invasive medical technology. Even with the numerous FDA-issued market clearances to his credit, all awarded based on FDA IRB-approved Level 1 clinical trials and the creation of a new product code OLI, Steven Shanks continues to look for opportunities where low-level laser as a medical modality can improve healthcare and the quality of life.